Canton Biologics’ Post

🎙️ Flashback: Illuminates the Future of Biopharmaceuticals At the recent conference, our Co-founder Sarfaraz K. Niazi shared a powerful narrative that's at the heart of ABYOLO's mission – transforming biosimilars from a concept to a global healthcare solution. Highlighting the intersection of innovation and accessibility: Explored how emerging technologies like CRISPR can revolutionize biosimilar development Emphasized the critical role of bioclusters in accelerating affordable biological treatments Demonstrated how personalized medicine and biosimilars can democratize healthcare globally His insights underscore ABYOLO's core belief: innovative biosimilars are key to making advanced treatments accessible to everyone, everywhere. Our journey continues – breaking barriers, one biosimilar at a time. #Biosimilars #HealthcareInnovation #AffordableMedicine #ABYOLO #BiotechnologyBreakthrough

⚕️We bring to you a NASDAQ story focused on evolving and optimizing living standards of people through bio technology innovation 🩻 Ticker (BBLG) on the NASDAQ In this episode of Capital Market Series, we bring you a NASDAQ story focused on improving the living conditions of degenerative bone problems that arise with age and/or abuse of body. With us is the President and CEO of BoneBiologics Jeff Frelick to discuss the novel research in providing a less invasive and efficient mechanisms to produce equal or better results that are currently on the market. With trials moving into the human phase in Australia, BoneBiologics is moving in the right direction for FDA approval. 🖥️ Full Episode here- https://lnkd.in/d4YNH64n In collaboration NewGen Mindset Daniel Kozel Alliance Advisors irlabs I Alyssa Barry, CPIR Johanna Gonzalez #biotech #healthcare #medical #fda #standardofliving #finance #investing #nasdaq #usa *Disclaimer:  None of the information provided in this episode should be considered investment advice and should only be viewed for informational purposes.

SFBN Feed: FDA ad comm favors Zevra’s Niemann-Pick drug https://lnkd.in/g7gd72nD Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we discuss the maneuverings of two interesting women in biotech: Verily alum [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

New Post: Petri Dish: Vertex kidney drug moves into Ph 3; Fractyl preps for commercialization -At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link

🚀 #BiotechTrends Mesoblast Ltd witnesses a dramatic share price surge—up 45.5%—post promising FDA discussions regarding their lead product, remestemcel-L. The #FDA has indicated that clinical data is sufficient to support a Biologics License Application, a significant step forward for the company's treatment for inflammatory diseases. 👩🔬💡 Investor confidence has rocketed, peaking share prices at 96 cents from 33 cents in just days. This climbing momentum marks investor optimism and forecasts a potentially vibrant market future for Mesoblast. While a recent pullback in share price has occurred, the market keenly awaits the official filing with the FDA. Mesoblast's outlook remains a subject of intrigue as stakeholders look towards a potential transformative impact on the company's market value and treatment contributions. 🌟📈 Read the full analysis and insight on how Mesoblast is shaping up to potentially revolutionize the biotech landscape: https://lnkd.in/gmQygRYE #Mesoblast #StockMarket #HealthcareInnovation #Investment #Biotechnology

As the FDA places greater emphasis on diversity in clinical trials, prioritizing diverse participant representation early in the drug development process is essential. Reflecting the populations most affected by specific conditions results in better health outcomes, accelerated approvals, and equitable access to life-saving therapies. At the Advancing Drug Development Forum (ADDF) next Thursday, our CEO, Sara Tylosky, will join industry leaders Courtney Cavaco, Susan Zelt, Andrew Marley, and Reginald Swift to discuss strategies for successful regulatory processes. Sara will highlight how Latin America is becoming a key player in global drug development, thanks to: 🌎 Diverse Patient Populations: Rich genetic variability that generates robust and meaningful data. ⏱️ Faster Recruitment: A large treatment-naïve population enables swift enrollment and high retention rates. 💰 Cost Efficiency: Lower operational costs without compromising research quality. 📋 Supportive Regulations: Streamlined approval processes in countries like Mexico and Argentina accelerate study start-up timelines. Join the discussion to explore how LATAM can help shape the future of drug development. 📅 When: December 12, 2024 📍 Where: Charles Hotel, Cambridge 👉 Register here: https://lnkd.in/e3ks4ZXW #DrugDevelopment #ClinicalTrials #ClinicalResearch #DiversityInResearch #ADDF2025 #LatinAmerica #LATAM

Thoughts on this? >> After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech

New Post: Petri Dish: Vertex kidney drug moves into Ph 3; Fractyl preps for commercialization -At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link At the start of this week, the focus was on Fractyl Health’s first earnings post-IPO and the company’s wide stock swings. Fractyl continued to share news later in the week, including a new executive appointment. Read more about Fractyl and other big biotech news from this week. Source link

I had the pleasure of meeting with Ingrid de Visser - Kamerling recently to discuss the progress of our ongoing Phase 2 study at the Centre for Human Drug Research (CHDR) and explore the evolving landscape of virus challenge studies in Europe. Looking forward to our continued collaboration and the promising paths ahead. #Biotech #ClinicalResearch #Innovation #Collaboration.

Thoughts on this? >> After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #biotech #healthcare